Xilio Therapeutics, Inc. (XLO): Price and Financial Metrics

Xilio Therapeutics, Inc. (XLO): $1.08

0.44 (+69.01%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

D

Add XLO to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#247 of 387

in industry

XLO Price/Volume Stats

Current price $1.08 52-week high $3.67
Prev. close $0.64 52-week low $0.49
Day low $1.05 Volume 34,539,200
Day high $1.93 Avg. volume 790,851
50-day MA $0.67 Dividend yield N/A
200-day MA $1.67 Market Cap 29.75M

XLO Stock Price Chart Interactive Chart >


Xilio Therapeutics, Inc. (XLO) Company Bio


Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune system for cancer patients. Its checkpoint inhibitor programs include XTX101, is a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1 clinical trials in patients with solid tumors; and cytokine programs comprise XTX202, XTX301, and XTX401, which are modified form of IL-2 that is masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.


XLO Latest News Stream


Event/Time News Detail
Loading, please wait...

XLO Latest Social Stream


Loading social stream, please wait...

View Full XLO Social Stream

Latest XLO News From Around the Web

Below are the latest news stories about XILIO THERAPEUTICS INC that investors may wish to consider to help them evaluate XLO as an investment opportunity.

Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data

Phase 1 combination dose escalation expected to support planned Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) Updated Phase 1 monotherapy data for XTX101 at the recommended Phase 2 dose (RP2D) continues to demonstrate minimal treatment-related adverse events, consistent with tumor-activated molecule design, and a 33% disease control rate across a range of late-line and IO refractory advanced solid tumors Previously reported confirmed partial response with XTX101 monotherapy

Yahoo | December 7, 2023

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results

Demonstrated initial clinical validation of tumor-selective activation technology for both XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, and XTX202, a tumor-activated, beta-gamma IL-2 On track to activate trial sites for XTX101 dose escalation in combination with atezolizumab under clinical collaboration with Roche in the fourth quarter of 2023 Reported initial Phase 1/2 data for XTX202, including a 50% disease control rate at higher doses (≥2.8 mg/kg), and plans to evaluate XTX202 as mono

Yahoo | November 9, 2023

Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors

Initial evidence of dose-dependent disease control rate with 50% disease control rate at higher doses (≥2.8 mg/kg) and 31% disease control rate across all dose levels in a range of solid tumor types, including cold tumors Treatment-related adverse events primarily Grade 1-2 at doses up to 4 mg/kg administered once every three weeks in outpatient setting, with no reported signs or symptoms of vascular leak syndrome Two patients continuing treatment for more than 1 year, demonstrating XTX202 was w

Yahoo | November 3, 2023

Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting

WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it will host an investor conference call and webcast on November 6, 2023 at 8:00 a.m. ET to review progress across its pipeline of tumor-activated molecules, including Phase 1/2 clinical data for XTX202, an investigational tumor-activated, engineered

Yahoo | October 31, 2023

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, California from November 1-5, 2023. The company plans to present preliminary anti-tumor activity, safety, pharmacokinetic and

Yahoo | September 27, 2023

Read More 'XLO' Stories Here

XLO Price Returns

1-mo 63.64%
3-mo 96.36%
6-mo -48.82%
1-year -63.39%
3-year N/A
5-year N/A
YTD 96.36%
2023 -79.55%
2022 -83.19%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!